[ {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0",
    "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ],
    "http://www.nanopub.org/nschema#hasAssertion" : [ {
      "@id" : "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#assertion"
    } ],
    "http://www.nanopub.org/nschema#hasProvenance" : [ {
      "@id" : "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#provenance"
    } ],
    "http://www.nanopub.org/nschema#hasPublicationInfo" : [ {
      "@id" : "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#pubinfo"
    } ]
  } ],
  "@id" : "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#Head"
}, {
  "@graph" : [ {
    "@id" : "http://purl.obolibrary.org/obo/DOID_8689",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Disease"
    } ]
  }, {
    "@id" : "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#association",
    "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ {
      "@id" : "http://purl.obolibrary.org/obo/DOID_8689"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ {
      "@id" : "https://w3id.org/biolink/vocab/treats"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ {
      "@id" : "https://identifiers.org/drugbank:DB01156"
    } ],
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "@value" : "\"Seizure disorder. ( 4 5.3 Current or prior diagnosis of bulimia or anorexia nervosa ( 4 5.3 Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, antiepileptic drugs. ( 4 5.3 Monoamine Oxidase Inhibitors (MAOIs): Do not use MAOIs intended to treat psychiatric disorders with bupropion hydrochloride extended-release tablets (XL) or within 14 days of stopping treatment with bupropion hydrochloride extended-release tablets (XL). Do not use bupropion hydrochloride extended-release tablets (XL) within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start bupropion hydrochloride extended-release tablets (XL) in a patient who is being treated with linezolid or intravenous methylene blue. ( 4 7.6 Known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride extended-release tablets (XL) ( 4 5.8  Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with seizure disorder.  Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with bupropion hydrochloride   Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and    Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with seizure disorder. Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with bupropion hydrochloride extended-release tablets (XL) [ see  Warnings and Precautions (5.3) Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [ see  Warnings and Precautions (5.3)   Drug Interactions (7.3) The use of MAOIs (intended to treat psychiatric disorders) concomitantly with bupropion hydrochloride extended-release tablets (XL) or within 14 days of discontinuing treatment with bupropion hydrochloride extended-release tablets (XL) is contraindicated. There is an increased risk of hypertensive reactions when bupropion hydrochloride extended-release tablets (XL) are used concomitantly with MAOIs. The use of bupropion hydrochloride extended-release tablets (XL) within 14 days of discontinuing treatment with an MAOI is also contraindicated. Starting bupropion hydrochloride extended-release tablets (XL) in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated [ see  Dosage and Administration (2.9)   Warnings and Precautions (5.4)   Drug Interactions (7.6) Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride extended-release tablets (XL). Anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported [ see  Warnings and Precautions (5.8)\""
    } ],
    "https://w3id.org/biolink/vocab/provided_by" : [ {
      "@id" : "https://w3id.org/um/NeuroDKG"
    } ],
    "https://w3id.org/biolink/vocab/relation" : [ {
      "@id" : "https://schema.org/MedicalContraindication"
    } ]
  }, {
    "@id" : "https://identifiers.org/drugbank:DB01156",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Drug"
    } ]
  } ],
  "@id" : "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#assertion"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#assertion",
    "http://www.w3.org/ns/prov#wasAttributedTo" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ]
  } ],
  "@id" : "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#provenance"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0",
    "http://purl.org/dc/terms/created" : [ {
      "@type" : "http://www.w3.org/2001/XMLSchema#dateTime",
      "@value" : "2021-08-23T12:42:57.559+02:00"
    } ],
    "http://purl.org/dc/terms/creator" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ {
      "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ {
      "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ {
      "@id" : "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY"
    } ]
  }, {
    "@id" : "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#sig",
    "http://purl.org/nanopub/x/hasAlgorithm" : [ {
      "@value" : "RSA"
    } ],
    "http://purl.org/nanopub/x/hasPublicKey" : [ {
      "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
    } ],
    "http://purl.org/nanopub/x/hasSignature" : [ {
      "@value" : "NY+eQcEAzcAHy6mXGLxq0ZWUy+DbAtkjO8jdVG3WPNkhJGjX7+GlbRba4gCdFma1LSMEMY9QzUXlN/vTG0L+VhxA4c9Ik8FityvKkMcfy8hOfjVZGfvYUdj6lnf4OD90Ila45r1EDAshg3p7oaSomsSGVfRhFNhpXAFBbGabUt8="
    } ],
    "http://purl.org/nanopub/x/hasSignatureTarget" : [ {
      "@id" : "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0"
    } ]
  } ],
  "@id" : "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#pubinfo"
} ]